No association between myeloproliferative neoplasms and the Crohn's disease-associated STAT3 predisposition SNP rs744166

Haematologica

Volumn 95, Issue 7, 2010, Pages 1226-1227

  Jones, Amy V ^a,b   Cross, Nicholas C P ^a,b  

^a WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Crohn's disease; Myeloproliferative neoplasm; STAT3

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 23 RECEPTOR; JANUS KINASE 2; STAT3 PROTEIN;

APLASTIC ANEMIA; AUTOIMMUNE DISEASE; CROHN DISEASE; GENE MAPPING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GIANT CELL ARTERITIS; HIGH RISK POPULATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LETTER; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PYROSEQUENCING; REITER SYNDROME; RHEUMATIC POLYMYALGIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL; TH17 CELL; GENETICS;

CROHN DISEASE; HUMANS; MYELOPROLIFERATIVE DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; STAT3 TRANSCRIPTION FACTOR;

EID: 77954526025     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.023390     Document Type: Letter

References (11)

1. Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, and Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95(7):1216-20.
2. Barrett JC, Hansoul S, Nicolae DL, Clio JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40(8): 955-62.
3. Wang K, Zhang H, Kugathasan S, Annese V, Bradfield JP, Russell RK, et al. Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease. Am J Hum Genet. 2009;84(3):399-405.
4. Brand S. Crohn's disease: Th1, Thl7 or both?; The change of a paradigm: new immunological and genetic insights implicate Thl7 cells in the pathogenesis of Crohn's disease. Gut. 2009;58(8):1152-67.
5. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446-9.
6. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450-4.
7. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-posittive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455-9.
8. Olcaydu D, Skoda RC, Looser R, Li S, Cazzola M, Pietra D, et al. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia. 2009;23(10):1924-6.
9. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia. N Engl J Med. 2005; 353(1):33-45.
10. Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood. 2006;107(8):3339-41.
11. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145): 661-78.